Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Midori Shima. (2022) Bispecific antibodies for the treatment of hemophilia A. Expert Opinion on Biological Therapy 22:8, pages 1029-1042.
Read now
Read now
Adam R. Root, Gurkan Guntas, Madan Katragadda, James R. Apgar, Jatin Narula, Chew Shun Chang, Sara Hanscom, Matthew McKenna, Jason Wade, Caryl Meade, Weijun Ma, Yongjing Guo, Yan Liu, Weili Duan, Claire Hendershot, Amy C. King, Yan Zhang, Eric Sousa, Amy Tam, Susan Benard, Han Yang, Kerry Kelleher, Fang Jin, Nicole Piche-Nicholas, Sinead E. Keating, Fernando Narciandi, Rosemary Lawrence-Henderson, Maya Arai, Wayne R. Stochaj, Kristine Svenson, Lidia Mosyak, Khetemcnee Lam, Christopher Francis, Kimberly Marquette, Liliana Wroblewska, H. Lily Zhu, Alfredo Darmanin Sheehan, Edward R. LaVallie, Aaron M. D’Antona, Alison Betts, Lindsay King, Edward Rosfjord, Orla Cunningham, Laura Lin, Puja Sapra, Lioudmila Tchistiakova, Divya Mathur & Laird Bloom. (2021) Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. mAbs 13:1.
Read now
Read now
Romain Ollier, Paul Wassmann, Thierry Monney, Christelle Ries Fecourt, Sunitha Gn, Vinu C A, Daniel Ayoub, Cian Stutz, Girish S Gudi & Stanislas Blein. (2019) Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development. mAbs 11:8, pages 1464-1478.
Read now
Read now
Yingda Xu, Dongdong Wang, Bruce Mason, Tony Rossomando, Ning Li, Dingjiang Liu, Jason K Cheung, Wei Xu, Smita Raghava, Amit Katiyar, Christine Nowak, Tao Xiang, Diane D. Dong, Joanne Sun, Alain Beck & Hongcheng Liu. (2019) Structure, heterogeneity and developability assessment of therapeutic antibodies. mAbs 11:2, pages 239-264.
Read now
Read now
Shunsuke Ito, Tatsuya Ikuno, Masayuki Mishima, Mariko Yano, Toshiko Hara, Taichi Kuramochi, Zenjiro Sampei, Tetsuya Wakabayashi, Mitsuyasu Tabo, Shuichi Chiba & Chiyomi Kubo. (2019) In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity. Journal of Immunotoxicology 16:1, pages 125-132.
Read now
Read now
Fatemeh Faraji, Zahra Karjoo, Maryam Vakili Moghaddam, Sahel Heidari, Reza Zolfaghari Emameh & Reza Falak. (2018) Challenges related to the immunogenicity of parenteral recombinant proteins: Underlying mechanisms and new approaches to overcome it. International Reviews of Immunology 37:6, pages 301-315.
Read now
Read now
Nobuo Sekiguchi, Chiyomi Kubo, Ayako Takahashi, Kumiko Muraoka, Akira Takeiri, Shunsuke Ito, Mariko Yano, Futa Mimoto, Atsuhiko Maeda, Yuki Iwayanagi, Tetsuya Wakabayashi, Shotaro Takata, Naoaki Murao, Shuichi Chiba & Masaki Ishigai. (2018) MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity. mAbs 10:8, pages 1168-1181.
Read now
Read now
Anette Karle, Sebastian Spindeldreher & Frank Kolbinger. (2016) Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. mAbs 8:3, pages 536-550.
Read now
Read now
Olga Obrezanova, Andreas Arnell, Ramón Gómez de la Cuesta, Maud E Berthelot, Thomas RA Gallagher, Jesús Zurdo & Yvette Stallwood. (2015) Aggregation risk prediction for antibodies and its application to biotherapeutic development. mAbs 7:2, pages 352-363.
Read now
Read now
Andrew Buchanan, Veronica Clementel, Rob Woods, Nicholas Harn, Michael A Bowen, Wenjun Mo, Bojana Popovic, Steven M. Bishop, William Dall’Acqua, Ralph Minter, Lutz Jermutus & Vahe Bedian. (2013) Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. mAbs 5:2, pages 255-262.
Read now
Read now
Frédéric Ducancel & Bruno H. Muller. (2012) Molecular engineering of antibodies for therapeutic and diagnostic purposes. mAbs 4:4, pages 445-457.
Read now
Read now
Ulrike Schick, Dorothy M Gujral, Tom M Richards, Kevin J Harrington & Christopher M Nutting. (2012) Zalutumumab in head and neck cancer. Expert Opinion on Biological Therapy 12:1, pages 119-125.
Read now
Read now
Tomoyuki Igawa, Hiroyuki Tsunoda, Taichi Kuramochi, Zenjiro Sampei, Shinya Ishii & Kunihiro Hattori. (2011) Engineering the variable region of therapeutic IgG antibodies. mAbs 3:3, pages 243-252.
Read now
Read now
Andreas Nechansky & Ralf Kircheis. (2010) Immunogenicity of therapeutics: a matter of efficacy and safety. Expert Opinion on Drug Discovery 5:11, pages 1067-1079.
Read now
Read now
Andreas M Hohlbaum & Arne Skerra. (2007) Anticalins®: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies. Expert Review of Clinical Immunology 3:4, pages 491-501.
Read now
Read now
Articles from other publishers (59)
M. Violet Lee, Ola M. Saad, Sylvia Wong, Jason LaMar, Lynn Kamen, Ben Ordonia, Rachel Melendez, Azadeh Hassanzadeh, Shan Chung & Surinder Kaur. (2023) Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development. Frontiers in Immunology 14.
Crossref
Crossref
Giuseppe Licari, Kyle P. Martin, Maureen Crames, Joseph Mozdzierz, Michael S. Marlow, Anne R. Karow-Zwick, Sandeep Kumar & Joschka Bauer. (2022) Embedding Dynamics in Intrinsic Physicochemical Profiles of Market-Stage Antibody-Based Biotherapeutics. Molecular Pharmaceutics 20:2, pages 1096-1111.
Crossref
Crossref
Adriana-Michelle Wolf Pérez, Nikolai Lorenzen, Michele Vendruscolo & Pietro Sormanni. 2022. Therapeutic Antibodies. Therapeutic Antibodies
57
113
.
Joshua M. Cohen, Xiaoping Ning, Yoel Kessler, Michele Rasamoelisolo, Verena Ramirez Campos, Michael J. Seminerio, Lynda J. Krasenbaum, Honglue Shen & Jennifer Stratton. (2021) Immunogenicity of biologic therapies for migraine: a review of current evidence. The Journal of Headache and Pain 22:1.
Crossref
Crossref
Helen Haixia Wu, Kerry-Leigh Ralph, Eliud Sepuldeva, Gale Hansen, Hua Li, Zhong-Fu Huang, Dongmei Liu, Michael Dziegelewski, Jennifer Ahlberg, Lee Frego, Steve Fogal, Susan van Tongeren, Christine Grimaldi, Tobias Litzenberger, David Presky, Sanjaya Singh, Scott Brodeur & Rachel Kroe-Barrett. (2021) An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases. International Journal of Pharmaceutics 609, pages 121162.
Crossref
Crossref
M. Giraud, P. Cathébras, X. Roblin, D. Thibaudin, S. Lamure, C. Mariat, S. Paul & M. Killian. (2021) Immunomonitoring du rituximab appliqué aux maladies auto-immunes : une aide pour la pratique clinique ?. La Revue de Médecine Interne 42:6, pages 384-391.
Crossref
Crossref
Sylvain Meunier, Marie de Bourayne, Moustafa Hamze, Aurélien Azam, Evelyne Correia, Catherine Menier & Bernard Maillère. (2020) Specificity of the T Cell Response to Protein Biopharmaceuticals. Frontiers in Immunology 11.
Crossref
Crossref
Brian R. Duke & Shibani Mitra-Kaushik. (2019) Current In Vitro Assays for Prediction of T Cell Mediated Immunogenicity of Biotherapeutics and Manufacturing Impurities. Journal of Pharmaceutical Innovation 15:2, pages 202-218.
Crossref
Crossref
Yi Wen, Suntara Cahya, Wei Zeng, Joanne Lin, Xiaoli Wang, Ling Liu, Laurent Malherbe, Robert Siegel, Andrea Ferrante & Arunan Kaliyaperumal. (2020) Development of a FRET-Based Assay for Analysis of mAbs Internalization and Processing by Dendritic Cells in Preclinical Immunogenicity Risk Assessment. The AAPS Journal 22:3.
Crossref
Crossref
Daruka Mahadevan, Mark C. Lanasa, Charles Farber, Manjari Pandey, Maria Whelden, Susan J. Faas, Terrie Ulery, Anjli Kukreja, Lan Li, Camille L. Bedrosian, Xiaoping Zhang & Leonard T. Heffner. (2019) Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Douglas Leipold & Saileta Prabhu. (2018) Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies. Clinical and Translational Science 12:2, pages 130-139.
Crossref
Crossref
Taichi Kuramochi, Tomoyuki Igawa, Hiroyuki Tsunoda & Kunihiro Hattori. 2019. Human Monoclonal Antibodies. Human Monoclonal Antibodies
213
230
.
Zenjiro Sampei, Kenta Haraya, Tatsuhiko Tachibana, Taku Fukuzawa, Meiri Shida-Kawazoe, Siok Wan Gan, Yuichiro Shimizu, Yoshinao Ruike, Shu Feng, Taichi Kuramochi, Masaru Muraoka, Takehisa Kitazawa, Yoshiki Kawabe, Tomoyuki Igawa, Kunihiro Hattori & Junichi Nezu. (2018) Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLOS ONE 13:12, pages e0209509.
Crossref
Crossref
Hanns‐Christian Mahler & Roman Mathäs. 2017. Process Scale Purification of Antibodies. Process Scale Purification of Antibodies
673
697
.
John H Sloan, Richard G Conway, Thomas G Pottanat, Jason S Troutt, Richard E Higgs, Robert J Konrad & Yue-Wei Qian. (2016) An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies. Bioanalysis 8:20, pages 2157-2168.
Crossref
Crossref
Wei Li, Ponraj Prabakaran, Weizao Chen, Zhongyu Zhu, Yang Feng & Dimiter Dimitrov. (2016) Antibody Aggregation: Insights from Sequence and Structure. Antibodies 5:3, pages 19.
Crossref
Crossref
Yan Q. Chen, Thomas G. Pottanat, Quincy L. Carter, Jason S. Troutt, Robert J. Konrad & John H. Sloan. (2016) Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodies. Journal of Immunological Methods 431, pages 45-51.
Crossref
Crossref
Priyanka Bhatt, Imran Vhora, Sushilkumar Patil, Jitendra Amrutiya, Chandrali Bhattacharya, Ambikanandan Misra & Rajashree Mashru. (2016) Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. Journal of Controlled Release 226, pages 148-167.
Crossref
Crossref
Hendrik Gille, Martin Hülsmeyer, Stefan Trentmann, Gabriele Matschiner, Hans Jürgen Christian, Todd Meyer, Ali Amirkhosravi, Laurent P. Audoly, Andreas M. Hohlbaum & Arne Skerra. (2015) Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class. Angiogenesis 19:1, pages 79-94.
Crossref
Crossref
Jesús Zurdo, Andreas Arnell, Olga Obrezanova, Noel Smith, Thomas Gallagher, Ramón de la Cuesta & Ben Locwin. 2015. Developability of Biotherapeutics. Developability of Biotherapeutics
221
290
.
Alexander Jarasch, Hans Koll, Joerg T. Regula, Martin Bader, Apollon Papadimitriou & Hubert Kettenberger. (2015) Developability Assessment During the Selection of Novel Therapeutic Antibodies. Journal of Pharmaceutical Sciences 104:6, pages 1885-1898.
Crossref
Crossref
S M Deyev, E N Lebedenko, L E Petrovskaya, D A Dolgikh, A G Gabibov & M P Kirpichnikov. (2015) Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering. Russian Chemical Reviews 84:1, pages 1-26.
Crossref
Crossref
Jesús Zurdo, Andreas Arnell, Olga Obrezanova, Noel Smith, Ramón Gómez de la Cuesta, Thomas R. A. Gallagher, Rebecca Michael, Yvette Stallwood, Caroline Ekblad, Lars Abrahmsén & Ingmarie Höidén-Guthenberg. (2015) Early Implementation of QbD in Biopharmaceutical Development: A Practical Example. BioMed Research International 2015, pages 1-19.
Crossref
Crossref
Alessandra VultaggioFrancesca NenciniSara PratesiGiulia PetroniEnrico MaggiAndrea Matucci. (2014) Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. Journal of Interferon & Cytokine Research 34:12, pages 946-952.
Crossref
Crossref
Margaret A. Lindorfer, Joost M. Bakker, Paul W.H.I. Parren & Ronald P. Taylor. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1733
1774
.
Bonita Rup, Corinna Krinos‐Fiorotti, Boris Gorovits & Hendrik Neubert. 2014. Biophysical Methods for Biotherapeutics. Biophysical Methods for Biotherapeutics
207
242
.
T. Kuramochi, T. Igawa, H. Tsunoda & K. Hattori. 2014. Human Monoclonal Antibodies. Human Monoclonal Antibodies
123
137
.
Vera Brinks, Daniel Weinbuch, Matthew Baker, Yann Dean, Philippe Stas, Stefan Kostense, Bonita Rup & Wim Jiskoot. (2013) Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins. Pharmaceutical Research 30:7, pages 1719-1728.
Crossref
Crossref
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, Takehisa Kitazawa, Kazutaka Yoshihashi, Aya Harada, Miho Funaki, Kenta Haraya, Tatsuhiko Tachibana, Sachiyo Suzuki, Keiko Esaki, Yoshiaki Nabuchi & Kunihiro Hattori. (2013) Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity. PLoS ONE 8:2, pages e57479.
Crossref
Crossref
Jonathan E Constance & Carol S Lim. (2012) Targeting malignant mitochondria with therapeutic peptides. Therapeutic Delivery 3:8, pages 961-979.
Crossref
Crossref
Andrew B NormanWilliam J Ball. (2012) Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody. Immunotherapy 4:3, pages 335-343.
Crossref
Crossref
. 2012. Therapeutic Antibody Engineering. Therapeutic Antibody Engineering
377
595
.
Bernard Maillère, Stéphanie Delluc & Gilles Ravot. (2012) La prédiction de l’immunogénicité des protéines thérapeutiques. médecine/sciences 28:1, pages 82-88.
Crossref
Crossref
. 2012. Therapeutic Antibody Engineering. Therapeutic Antibody Engineering
459
595
.
Meenu Wadhwa & Robin Thorpe. 2011. Detection and Quantification of Antibodies to Biopharmaceuticals. Detection and Quantification of Antibodies to Biopharmaceuticals
37
56
.
Stephanie Delluc, Gilles Ravot & Bernard Maillere. (2011) Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. The FASEB Journal 25:6, pages 2040-2048.
Crossref
Crossref
Etsuji Kaneko & Rinpei Niwa. (2011) Optimizing Therapeutic Antibody Function. BioDrugs 25:1, pages 1-11.
Crossref
Crossref
Satish Kumar Singh. (2011) Impact of Product-Related Factors on Immunogenicity of Biotherapeutics. Journal of Pharmaceutical Sciences 100:2, pages 354-387.
Crossref
Crossref
F. Chowdhury, A.L. Tutt, C. Chan, M. Glennie & P.W. Johnson. (2010) Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum. Journal of Immunological Methods 363:1, pages 1-8.
Crossref
Crossref
Danika Wullner, Lei Zhou, Erica Bramhall, Andrew Kuck, Theresa J. Goletz, Steven Swanson, Narendra Chirmule & Vibha Jawa. (2010) Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clinical Immunology 137:1, pages 5-14.
Crossref
Crossref
Vasco Filipe, Andrea Hawe, Huub Schellekens & Wim Jiskoot. 2010. Aggregation of Therapeutic Proteins. Aggregation of Therapeutic Proteins
403
433
.
Meenu Wadhwa & Robin Thorpe. (2010) Unwanted immunogenicity: lessons learned and future challenges. Bioanalysis 2:6, pages 1073-1084.
Crossref
Crossref
K.W. Woodburn, P.J. Schatz, K-L. Fong & P. Beaumier. (2010) Erythropoiesis Equivalence, Pharmacokinetics and Immune Response following Repeat Hematide™ Administration in Cynomolgus Monkeys. International Journal of Immunopathology and Pharmacology 23:1, pages 121-129.
Crossref
Crossref
Philippe Alard, Johan Desmet & Ignace Lasters. 2010. Antibody Engineering. Antibody Engineering
369
376
.
P. Stas, Y. Gansemans & I. Lasters. 2010. Current Trends in Monoclonal Antibody Development and Manufacturing. Current Trends in Monoclonal Antibody Development and Manufacturing
271
291
.
Philippe Stas, Ignace Lasters & Traduction française de Laure Coulombel. (2009) Immunogénicité de protéines d’intérêt thérapeutique. médecine/sciences 25:12, pages 1070-1077.
Crossref
Crossref
Andreas Baumann. (2009) Nonclinical development of biopharmaceuticals. Drug Discovery Today 14:23-24, pages 1112-1122.
Crossref
Crossref
Si-Han Hai, Julie A. McMurry, Paul M. Knopf, William Martin & Anne S. De Groot. 2009. Therapeutic Monoclonal Antibodies. Therapeutic Monoclonal Antibodies
417
437
.
Georg-Burkhard Kresse. (2009) Biosimilars – Science, status, and strategic perspective. European Journal of Pharmaceutics and Biopharmaceutics 72:3, pages 479-486.
Crossref
Crossref
Philippe Stas, Jurgen Pletinckx, Yannick Gansemans & Ignace Lasters. 2009. Recombinant Antibodies for Immunotherapy. Recombinant Antibodies for Immunotherapy
20
42
.
Michaela Gebauer & Arne Skerra. (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Current Opinion in Chemical Biology 13:3, pages 245-255.
Crossref
Crossref
Caroline Grönwall & Stefan Ståhl. (2009) Engineered affinity proteins—Generation and applications. Journal of Biotechnology 140:3-4, pages 254-269.
Crossref
Crossref
Sigrid R. Ruuls, Jeroen J. Lammerts van Bueren, Jan G. J. van de Winkel & Paul W. H. I. Parren. (2008) Novel human antibody therapeutics: The age of the Umabs. Biotechnology Journal 3:9-10, pages 1157-1171.
Crossref
Crossref
Harald Kropshoffer & Thomas Singer. 2008. Immunotoxicology Strategies for Pharmaceutical Safety Assessment. Immunotoxicology Strategies for Pharmaceutical Safety Assessment
361
372
.
Patrick G Swann, Mate Tolnay, Subramanian Muthukkumar, Marjorie A Shapiro, Barbara L Rellahan & Kathleen A Clouse. (2008) Considerations for the development of therapeutic monoclonal antibodies. Current Opinion in Immunology 20:4, pages 493-499.
Crossref
Crossref
Paul Chamberlain. 2008. Immunogenicity of Biopharmaceuticals. Immunogenicity of Biopharmaceuticals
239
258
.
Charlotte Magdelaine-Beuzelin, Quentin Kaas, Vanessa Wehbi, Marc Ohresser, Roy Jefferis, Marie-Paule Lefranc & Hervé Watier. (2007) Structure–function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Critical Reviews in Oncology/Hematology 64:3, pages 210-225.
Crossref
Crossref
Anne S. De Groot & David W. Scott. (2007) Immunogenicity of protein therapeutics. Trends in Immunology 28:11, pages 482-490.
Crossref
Crossref
Arne Skerra. (2007) Alternative non-antibody scaffolds for molecular recognition. Current Opinion in Biotechnology 18:4, pages 295-304.
Crossref
Crossref